Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin for antipsychotic-induced dyslipidemia
NCT04761861Phase 2Withdrawn
- Sponsor
- Sadat City University
- Start
- Feb 2021
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in dyslipidemia comparing Vildagliptin Arm with Placebo Arm (2 arms). Primary endpoint: low-density lipoprotein cholesterol at 12 weeks. Planned start Feb 2021; status: withdrawn.
02
Drugs
vildagliptin
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT04761861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04761861.